Caseware UK (AP4) 2025.0.111 2025.0.111 2025-12-31 2025-12-31 false true 2 2025-01-01 true Research and experimental development 2 false 06456614 2025-01-01 2025-12-31 06456614 2024-01-01 2024-12-31 06456614 2025-12-31 06456614 2024-12-31 06456614 c:Director4 2025-01-01 2025-12-31 06456614 d:CurrentFinancialInstruments 2025-12-31 06456614 d:CurrentFinancialInstruments 2024-12-31 06456614 d:ShareCapital 2025-12-31 06456614 d:ShareCapital 2024-12-31 06456614 d:OtherMiscellaneousReserve 2025-01-01 2025-12-31 06456614 d:OtherMiscellaneousReserve 2025-12-31 06456614 d:OtherMiscellaneousReserve 2024-12-31 06456614 d:RetainedEarningsAccumulatedLosses 2025-01-01 2025-12-31 06456614 d:RetainedEarningsAccumulatedLosses 2025-12-31 06456614 d:RetainedEarningsAccumulatedLosses 2024-12-31 06456614 c:EntityHasNeverTraded 2025-01-01 2025-12-31 06456614 c:FRS102 2025-01-01 2025-12-31 06456614 c:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 06456614 c:FullAccounts 2025-01-01 2025-12-31 06456614 c:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 06456614 e:PoundSterling 2025-01-01 2025-12-31 iso4217:GBP xbrli:pure

Registered number: 06456614 AVEO PHARMA LIMITED UNAUDITED FINANCIAL STATEMENTS INFORMATION FOR FILING WITH THE REGISTRAR FOR THE YEAR ENDED 31 DECEMBER 2025
AVEO PHARMA LIMITED REGISTERED NUMBER: 06456614 BALANCE SHEET AS AT 31 DECEMBER 2025
|  | 2025 |  | 2024
Note |  | £ |  | £
Current assets |  |  |  |  |
Debtors: amounts falling due within one year | 3 | 646,113 |  | 646,113 |
|  | 646,113 |  | 646,113 |
Total assets less current liabilities |  |  | 646,113 |  | 646,113
Net assets |  |  | 646,113 |  | 646,113
Capital and reserves |  |  |  |  |
Called up share capital |  |  | 2 |  | 2
Other reserves | 4 |  | 5,076,155 |  | 5,076,155
Profit and loss account | 4 |  | (4,430,044) |  | (4,430,044)
|  |  | 646,113 |  | 646,113
For the year ended 31 December 2025 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006. Members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements. The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities. The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime. The financial statements were approved and authorised for issue by the board and were signed on its behalf by:
................................................ Danielle Holland
Director
Date: 6 August 2026
The notes on page 2 form part of these financial statements. Page 1
AVEO PHARMA LIMITED NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025
1. | General information
AVEO Pharma Limited (the Company) is a company incorporated in the United Kingdom under the Companies Act. The Company is a private company limited by shares and is registered in England and Wales.The address of the Company’s registered office is 5th Floor Halo, Counterslip, Bristol, BS1 6AJ. The Company’s functional and presentational currency is pounds sterling (GBP) and the financial statements are rounded to the nearest pound (£). 2.Accounting policies
| 2.1 | Basis of preparation of financial statements
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
3. | Debtors
|  |  |  |  | 2025 | 2024
|  |  |  |  | £ | £
| Amounts owed by group undertakings | 646,113 | 646,113
4. | Reserves
Other reserves Other reserves represents the amount relating to additional paid in capital which exceeds the nominal value of the shares and represents the capital contribution. Profit and loss account Profit and loss account represents the cumulative profits or losses net of dividends paid and other adjustments.
5. | Controlling party
The parent company is AVEO Pharmaceuticals, Inc. (registered and incorporated in the United States of America). The largest and smallest group in which the results of the company are consolidated is that headed by AVEO Pharmaceuticals Inc. The consolidated accounts of this company are available to the public and may be obtained from www.aveooncology.com. The ultimate parent company is LG Chem, Ltd. (incorporated in the Republic of Korea). The directors of the company do not consider there to be an ultimate controlling party.
Page 2